Jump to content
Sign in to follow this  


Recommended Posts

Solid Biosciences (NASDAQ:SLDB) initiated with Sell rating and $25 (27% downside risk) price target at Citigroup citing scant market opportunity for DMD candidate SGT-001 compared to Sarepta's and Pfizer's offerings. Shares are down 1% premarket.

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

  • Recently Browsing   0 members

    No registered users viewing this page.

  • Donate

    Please donate to support this community. We appreciate all donations!

    Donate Sidebar by DevFuse
  • Upcoming Events

    No upcoming events found
  • Forum Statistics

    • Total Topics
    • Total Posts
  • Who's Online (See full list)